Grid Africa and TCL Solar link on energy solutions in Zimbabwe and Zambia
Pan-African energy developer Grid Africa has partnered strategically with TCL Solar, a photovoltaic technology provider, to deliver innovative distributed energy solutions to Zimbabwe and Zambia.
The initiative will utilise advanced solar and battery storage technologies to bolster regional energy security and foster economic growth.
Sub-Saharan Africa faces a critical energy shortage, with many nations struggling to supply consistent and reliable electricity to meet rising demands.
The regional energy landscape is changing with heightened trading activity and the consolidation of the Southern Africa Power Pool, offering a unique opportunity to bypass conventional infrastructure development.
Zimbabwe and Zambia, with their robust transmission networks and recent regulatory changes promoting easier grid access, offer a promising landscape for the swift deployment of distributed energy systems.
Grid Africa CEO Norman Moyo stated: "There is a solution to the crisis if we embrace new emerging technologies that are immediately available and quick to deploy. We have a unique opportunity to reverse engineer our over-reliance on utilities by deploying distributed solutions that leverage existing transmission and distribution infrastructure.
'Just as we successfully revolutionised telecommunications with GSM [Global System for Mobile Communication] technology, we can apply the same mindset to solve our energy security challenges."
TCL Solar aims to deploy 100MW of distributed energy solutions in the two countries. The collaboration will require efficient supply chain management to ensure prompt and effective implementation.
TCL Solar Middle East and Africa stated: "In partnering with Grid Africa, we are excited to contribute to a sustainable energy future for the region.
'Targeting the high temperature and high irradiation environment of Zimbabwe and Zambia, TCL Solar optimised the existing module design by following the advanced TOPCon passivation structural technology patents of SunPower, improved the thermal resistance and power generation capacity of the modules."
In a related development, Zambia recently announced plans to resume construction on the Zambia-Tanzania Interconnector Project, linking its power grid to East Africa.
"Grid Africa and TCL Solar link on energy solutions in Zimbabwe and Zambia" was originally created and published by Power Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These results demonstrated robust overall reduction in the monthly attack rate (92% mean and 97% median). These results further support navenibart's favorable safety and tolerability profile, and potential every three- (Q3M) and every six-month (Q6M) dosing regimens. 'We are thrilled to share positive initial results from the ALPHA-SOLAR long-term open-label trial,' said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics. 'Results are consistent with navenibart's best-in-class profile that we saw in the ALPHA-STAR Phase 1b/2 trial. With now 12 to 18 months on navenibart, these ALPHA-SOLAR results support navenibart's favorable profile and the potential to administer navenibart every 3 and every 6 months. The Phase 3 ALPHA-ORBIT trial is evaluating both every 3- and every 6-month regimens and is actively enrolling patients. Navenibart's profile and results that we have seen to date demonstrate the potential for navenibart to be the market-leading HAE therapy.' 'The navenibart results in patients to date support the potential for patients to have long-acting protection from their HAE attacks with very low treatment burden,' said Dr. William Yang, M.D., PRCPC, FAAAAI, Chair, Ottawa Allergy Research Corporation and Red Maple Trials Inc. 'We are excited for the Phase 3 ALPHA-ORBIT trial and believe that navenibart's profile with infrequent dosing could allow patients to spend less time thinking about their HAE, and more time living their lives.' ALPHA-SOLAR is a long-term open-label trial in adults with HAE Type 1 or 2 designed to assess long-term safety and efficacy of navenibart. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial elected to enroll in ALPHA-SOLAR. ALPHA-STAR patients from Cohorts 1 and 2 enrolled in Arm A, and ALPHA-STAR patients from Cohort 3 enrolled in Arm B (described in the table below). Initial results from ALPHA-SOLAR 1: Comparisons to baseline from ALPHA-STAR. Navenibart demonstrated overall attack-freedom of 50% over six months, which is the longest period of follow-up for all 16 patients to date. All patients remain in the ALPHA-SOLAR trial. Navenibart was well-tolerated with no severe or serious treatment-emergent adverse events (TEAEs) and no discontinuations. One participant experienced two treatment-related, mild injection site reactions that resolved without treatment. There were no injection site reactions of pain. The safety profile of navenibart in patients with HAE was favorable through more than 17 months (median / mean) of cumulative follow-up since the initiation of navenibart in ALPHA-STAR. The results shared above are available in a poster presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress on June 13, 2025. The poster is accessible to conference attendees and also in the Scientific Presentations and Publications section of In February 2025, Astria initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is evaluating navenibart administered Q3M and Q6M and currently enrolling patients. For more information, visit NCT06842823 or About Navenibart: Navenibart is a monoclonal antibody inhibitor of plasma kallikrein in development for the treatment of HAE. Our goal with navenibart is to provide rapid and sustained HAE attack prevention with a validated mechanism and trusted modality administered subcutaneously every 3 and 6 months. We aim to empower people living with HAE to live life without limitations from their disease. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn. Forward Looking Statements: This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: our expectations regarding the potential significance of the results from the navenibart Phase 1b/2 ALPHA-STAR clinical trial and initial results from the ALPHA-SOLAR trial; the goals and objectives of the ALPHA-ORBIT trial; the potential therapeutic benefits of navenibart as a treatment for HAE; the potential attributes and profile of navenibart as a treatment for HAE, including its potential to be a life-changing, market leading preventative treatment for HAE, and our overall vision and goals for the navenibart program; and our corporate strategy and vision, including our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'goals,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or "vision," and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Astria's product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies may not be replicated in clinical trials, that the preliminary, initial or interim results from clinical trials may not be indicative of the final results, that the results of early stage clinical trials, such as the results from the ALPHA-STAR Phase 1b/2 clinical trial, may not be replicated in later stage clinical trials, such as the planned Phase 3 development program, the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; decisions made by, and feedback received from, the U.S. Food and Drug Administration and other regulatory authorities on our regulatory and clinical trial submissions and other feedback from potential clinical trial sites, including investigational review boards at such sites, and other review bodies with respect to navenibart, STAR-0310, and any other future development candidates; our ability to manufacture sufficient quantities of drug substance and drug product for navenibart, STAR-0310, and any other future product candidates on a cost-effective and timely basis, and to develop dosages and formulations for navenibart, STAR-0310, and any other future product candidates that are patient-friendly and competitive; our ability to develop biomarker and other assays, along with the testing protocols therefor; our ability to obtain, maintain and enforce intellectual property rights for navenibart, STAR-0310 and any other future product candidates; our potential dependence on collaboration partners; competition with respect to navenibart, STAR-0310, or any of our other future product candidates; the risk that survey results, modeling data and market research may not be accurate predictors of the commercial landscape for HAE, the ability of navenibart to compete in HAE and the anticipated position and attributes of navenibart in HAE based on clinical data to date, its preclinical profile, pharmacokinetic modeling, market research and other data; risks that any of our clinical trials of STAR-0310 may not commence, continue or be completed on time, or at all; risks that results of preclinical studies of STAR-0310 will not be replicated in clinical trials; our ability to manage our cash usage and the possibility of unexpected cash expenditures; our ability to obtain necessary financing to conduct our planned activities and to manage unplanned cash requirements; the risks and uncertainties related to our ability to recognize the benefits of any additional acquisitions, licenses or similar transactions; and general economic and market conditions; as well as the risks and uncertainties discussed in the 'Risk Factors' section of our Annual Report on Form 10-K for the period ended December 31, 2024 and in other filings that we may make with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Astria may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on Astria's forward-looking statements. Neither Astria, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Astria's views as of any date subsequent to the date hereof.
Yahoo
5 hours ago
- Yahoo
TCL Solar Showcases Next-Gen BC Modules at SNEC, Writing the Future of Solar Innovation with Technological Advancements
SHANGHAI, June 13, 2025 /CNW/ -- From June 11th to 13th, the 18th International Solar Photovoltaic and Smart Energy Conference & Exhibition (SNEC PV+ 2025) was held at the National Exhibition and Convention Center in Shanghai. During the event, TCL Solar exhibited its next-generation back-contact (BC) module technology, a range of high-efficiency, high-power BC and TOPCon modules, as well as parent company TCL Zhonghuan's 210 monocrystalline silicon ingots and wafer products. The company also introduced lightweight module "concept products" and new anti-dust accumulation series. TCL Solar's showcased BC modules achieved a maximum power output of 680W and a record efficiency of 25.2%, while its TOPCon modules reached up to 750W and 24.14% efficiency. The Next-Gen BC Product Presentation that with continued advancements in low-cost metallization for BC cells, optimized polysilicon passivation layers, and high-density packaging technologies, the cost of TCL Solar's BC products will further approach that of TOPCon. Meanwhile, the bifaciality of BC modules will exceed 80%, with module efficiency surpassing 25%. Leveraging its technological expertise, patent portfolio, and global market channels in BC technology, TCL Solar will collaborate closely with upstream and downstream partners to foster the BC industry ecosystem and drive down the LCOE for solar power. Additionally, based on market insights and customer needs, TCL Solar launched its new anti-dust shingled modules at SNEC and, in collaboration with Lens Technology, unveiled an innovative lightweight module series—delivering high performance and reliability tailored to customer demands. On June 12th, TCL Solar's representative provided a comprehensive analysis of the company's full range of module products in the Application Value Analysis of Distributed Solar Products in China, detailing their performance characteristics and differentiated value propositions. Since the second half of 2024, TCL Solar has been advancing upgrades across technology, manufacturing, product offerings, branding, and market expansion. The company has now established a diversified portfolio encompassing BC, TOPCon, half-cut, and shingled technologies, providing customers with highly efficient, reliable, and value-driven solutions for all application scenarios. "Double Certification Triumph: TCL SOLAR Conquers Extreme Cold and Global Markets with Cutting-Edge Tech" During this event, TCL SOLAR achieved two milestone certifications: China's first low-temperature dual certification (power degradation <0.5% at -40°C) and TÜV Rheinland's global certification for N-type BC modules, solidifying its extreme-environment leadership. The BC modules feature -0.26%/°C temperature coefficient, 10% higher shading tolerance, and 0.35% annual degradation, setting new reliability benchmarks. With concurrent UK MCS, Japan JAPC, Colombia RETIE, and Dubai DEWA certifications, TCL SOLAR accelerates global expansion via "certification + localization" strategy, empowering energy transition in polar and emerging markets. As a technology-driven enterprise, TCL Solar remains at the forefront of industry innovation. Guided by China's "dual-carbon" goals, TCL Solar continues to empower the entire supply chain with cutting-edge advancements, underpinned by world-class manufacturing capabilities. Through its commitment to zero-carbon practices and industry transformation, TCL Solar not only drives continuous reductions in solar LCOE but also sets a benchmark for high-quality development, contributing to global sustainable energy solutions. View original content to download multimedia: SOURCE TCL Solar View original content to download multimedia:
Yahoo
11 hours ago
- Yahoo
SNEC 2025: Sungrow Showcases Industry-Leading Renewable Energy Solutions
SHANGHAI, June 13, 2025 /PRNewswire/ -- Sungrow, the global leading PV inverter and energy storage system supplier, is presenting its comprehensive renewable energy portfolio at SNEC 2025, held from June 11 to 13 in Shanghai. Highlights include the next-generation 1+X 2.0 Modular Inverter for utility-scale PV projects, the advanced PowerTitan 3.0 Energy Storage System (ESS) platform, cutting-edge grid-forming technologies, EV charging solutions, and a diverse range of offerings for distributed generation. 1+X 2.0 Modular Inverter: Powering the Future of Utility-Scale Solar Catering to the utility-scale market, Sungrow debuted its latest 1+X 2.0 Modular Inverter. Winner of the iF Design Award, this inverter introduces greater modularity with a scalable block design ranging from 800kW to 9.6MW. The product's split modular design isolates critical components (IGBTs, capacitors) in the upper inverter module for quick field replacement. Operation and Maintenance (O&M) time is slashed to one hour per module swap—the easy O&M enables field engineers to perform quick replacements. The new inverter delivers outstanding reliability, featuring IP66 protection and stable operation without derating at high temperatures up to 45°C. It also incorporates AI-driven fault detection, AI-enhanced DC-side safety management, and advanced grid-forming capabilities—meeting the industry's high standards for performance, availability, and reliability. For more information, please click here. PowerTitan 3.0 ESS Platform: Setting a New Benchmark for Utility-Scale ESS Sungrow's PowerTitan 3.0 sets a new benchmark for utility-scale energy storage through unmatched flexibility, energy density, and intelligence. Offered in 10ft Flex (3.45MWh), 20ft Class (6.9MWh), and 30ft Plus (12.5MWh) versions, it supports durations from 2 to 12 hours and operates reliably in extreme conditions. The flagship 30ft Plus version is the world's largest BESS in both capacity and power density, featuring 684Ah stacking battery cells and delivering up to 12.5MW/50MWh per block, achieving over 500kWh per square meter in power density. In addition, the PowerTitan 3.0 adopts all-in-one AC-DC block design architecture, its power density accounts for both the battery system and the power conversion system (PCS). Excluding the PCS, the battery alone achieves an impressive energy density of 570kWh per square meter. This high integration helps reducing land footprint by 45% and cabling by 10%, significantly lowering CAPEX for customers. In terms of energy efficiency, with an all-in-one AC-DC block design, stacking battery cell, and liquid-cooled silicon carbide (SiC) PCS, the platform achieves an industry-leading round-trip efficiency (RTE) of 93.5%. From a safety perspective, as system capacity scales up and long-duration energy storage advances, the risks associated with parasitic balancing currents and short-circuit currents increase significantly. The PowerTitan 3.0 integrates standard short cables within the liquid-cooled container, enabling DC cables stay inside the container. This effectively eliminates the risk of DC-side short circuits while also addressing the issue of parasitic balancing currents between clusters, further reinforcing its safety advantages. C&I Solutions: Empowering Every Business As industrial and commercial users strive to cut emissions and control energy costs, Sungrow's C&I energy solutions offer reliable and scalable clean energy. Among the highlights is Sungrow's latest C&I liquid-cooled ESS, the PowerStack 255CS. Equipped with advanced 314Ah battery cells, it offers flexible power capacities—257kWh (2-hour system) or 514kWh (4-hour system)—along with over 90% round-trip efficiency and a 20-year design life. Fully integrated with PCS, EMS, and BMS, and certified under stringent global safety standards such as UL9540 and NFPA855/69/68/14, the system ensures seamless operation across a wide range of scenarios, including C&I standalone ESS, PV plus ESS, EV chargers plus ESS, and microgrids. Also on display is the SH125CX, a powerful 125kW hybrid inverter. Combined with PowerStack 255CS, it forms a fully DC-coupled solution ideal for medium and large-scale C&I projects. Additional smart devices such as power optimizers and rapid shutdown units further enhance energy yields and safety—optimizing every kilowatt and maximizing return on investment. Residential Solutions Offers Greater Independence, Reliability, and Efficiency As the region experiences rapid urbanization and rising energy costs, there is a clear shift toward residential solar-plus-storage solutions that offer greater independence, reliability, and efficiency. Sungrow's residential portfolio is designed in response to these needs, setting a new benchmark for intelligent and user-centric home energy management. A highlight is the upcoming residential low-voltage ESS solution MG5/6/8/10RL hybrid inverter series (up to 10kW), combined with the MGL060 battery (6kWh each). This next-generation solution is flexible, robust, user-friendly, and fully optimized for home energy needs, with the official launch coming soon. Sungrow also presents its full lineup of microinverters (450W–2,000W), designed for various residential applications such as balconies and rooftops. With more power generation, plug-and-play functionality, and one-click network configuration, Sungrow provides users with a more efficient and convenient experience. In addition to its solar and storage solutions, Sungrow also showcased its EV charging portfolio, featuring the 480kW ultra-fast charger with advanced isolated air-cooling technology, and the 7kW AC charger designed to meet the needs of both commercial and residential users. About Sungrow Sungrow, a global leader in renewable energy technology, has pioneered sustainable power solutions for over 28 years. As of December 2024, Sungrow had installed 740 GW of power electronic converters worldwide. The Company is recognized as the world's No. 1 on PV inverter shipments (S&P Global Commodity Insights) and the world's most bankable energy storage company (BloombergNEF). Its innovations power clean energy projects across the globe, supported by a network of 520 service outlets guaranteeing excellent customer experience. At Sungrow, we're committed to bridging to a sustainable future through cutting-edge technology and unparalleled service. For more information, please visit: View original content to download multimedia: SOURCE Sungrow Power Supply Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
